Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia

Abstract Background Expression of Bcr-Abl in hematopoietic stem cells is sufficient to cause chronic myeloid leukemia (CML) and tyrosine kinase inhibitors (TKI) induce molecular remission in the majority of CML patients. However, the disease driving stem cell population is not fully targeted by TKI...

Cijeli opis

Bibliografski detalji

Glavni autori:	Oliver Herrmann, Maja Kim Kuepper, Marlena Bütow, Ivan G. Costa, Iris Appelmann, Fabian Beier, Tom Luedde, Till Braunschweig, Steffen Koschmieder, Tim H. Brümmendorf, Mirle Schemionek
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2019-07-01
Serija:	BMC Cancer
Teme:	CML Leukemic stem cells Inflammation Tyrosine kinase inhibitor Infliximab TNF
Online pristup:	http://link.springer.com/article/10.1186/s12885-019-5871-2
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!